KNSA
Price:
$24.93
Market Cap:
$1.78B
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin cond...[Read more]
Industry
Biotechnology
IPO Date
2018-05-25
Stock Exchange
NASDAQ
Ticker
KNSA
According to Kiniksa Pharmaceuticals, Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -166.20. This represents a change of 497.95% compared to the average of -27.80 of the last 4 quarters.
The mean historical PE Ratio of Kiniksa Pharmaceuticals, Ltd. over the last ten years is 4.15. The current -166.20 PE Ratio has changed -400700.28% with respect to the historical average. Over the past ten years (40 quarters), KNSA's PE Ratio was at its highest in in the December 2022 quarter at 58.44. The PE Ratio was at its lowest in in the June 2024 quarter at -81.76.
Average
4.15
Median
-5.94
Minimum
-26.37
Maximum
87.25
Discovering the peaks and valleys of Kiniksa Pharmaceuticals, Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.44%
Maximum Annual PE Ratio = 87.25
Minimum Annual Increase = -210.90%
Minimum Annual PE Ratio = -26.37
Year | PE Ratio | Change |
---|---|---|
2023 | 87.25 | 1.44% |
2022 | 5.67 | -210.90% |
2021 | -5.11 | -24.52% |
2020 | -6.77 | 83.35% |
2019 | -3.69 | -54.07% |
2018 | -8.04 | -17.48% |
2017 | -9.74 | -63.05% |
The current PE Ratio of Kiniksa Pharmaceuticals, Ltd. (KNSA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
29.27
5-year avg
15.47
10-year avg
4.15
Kiniksa Pharmaceuticals, Ltd.’s PE Ratio is less than Nuvalent, Inc. (-32.10), less than Ventyx Biosciences, Inc. (-0.89), less than Arcellx, Inc. (-70.75), less than Cullinan Oncology, Inc. (-6.96), less than Day One Biopharmaceuticals, Inc. (-7.39), less than Structure Therapeutics Inc. (-18.15), less than Karuna Therapeutics, Inc. (-29.52), less than Phathom Pharmaceuticals, Inc. (-3.49), less than Replimune Group, Inc. (-3.26), less than Nuvectis Pharma, Inc. (-4.95), less than Lyra Therapeutics, Inc. (-0.18), less than Kronos Bio, Inc. (-0.58), less than Gossamer Bio, Inc. (-2.55), less than Cogent Biosciences, Inc. (-4.58), less than Larimar Therapeutics, Inc. (-8.80), less than Kura Oncology, Inc. (-9.19), less than Cerevel Therapeutics Holdings, Inc. (-17.73), less than Spero Therapeutics, Inc. (4.06), less than Bolt Biotherapeutics, Inc. (-0.37), less than Coherus BioSciences, Inc. (-4.85), less than Gracell Biotechnologies Inc. (-12.26), less than Neoleukin Therapeutics, Inc. (-0.98),
Company | PE Ratio | Market cap |
---|---|---|
-32.10 | $5.59B | |
-0.89 | $153.35M | |
-70.75 | $3.83B | |
-6.96 | $1.04B | |
-7.39 | $1.25B | |
-18.15 | $2.11B | |
-29.52 | $12.60B | |
-3.49 | $1.21B | |
-3.26 | $708.49M | |
-4.95 | $115.27M | |
-0.18 | $17.85M | |
-0.58 | $59.36M | |
-2.55 | $205.87M | |
-4.58 | $1.15B | |
-8.80 | $513.64M | |
-9.19 | $1.48B | |
-17.73 | $8.19B | |
4.06 | $71.07M | |
-0.37 | $24.78M | |
-4.85 | $142.86M | |
-12.26 | $989.87M | |
-0.98 | $8.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kiniksa Pharmaceuticals, Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kiniksa Pharmaceuticals, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Kiniksa Pharmaceuticals, Ltd.'s PE Ratio?
How is the PE Ratio calculated for Kiniksa Pharmaceuticals, Ltd. (KNSA)?
What is the highest PE Ratio for Kiniksa Pharmaceuticals, Ltd. (KNSA)?
What is the 3-year average PE Ratio for Kiniksa Pharmaceuticals, Ltd. (KNSA)?
What is the 5-year average PE Ratio for Kiniksa Pharmaceuticals, Ltd. (KNSA)?
How does the current PE Ratio for Kiniksa Pharmaceuticals, Ltd. (KNSA) compare to its historical average?